We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Hvivo Plc | HVO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.35 | -1.22% | 28.25 | 16:12:45 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 28.50 | 28.25 | 28.50 | 28.25 | 28.60 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 25/04/2023 | Special | GBP | 0.0045 | 04/05/2023 | 05/05/2023 | 09/06/2023 |
| Top Posts |
|---|
Posted at 11/4/2024 13:47 by sikhthetech Baldrick, TLY has a diversified business model, treating millions of patients.Revenues H1 were £55m, which is similar to HVO's fy2023. TLY Mcap £8m, whereas HVO £197m My assertion is HVO's business model is questionable. HVO CEO has 7m options for a reason - to talk up the company. |
Posted at 11/4/2024 11:51 by sikhthetech Chica,That backs up my previous point about indian companies being capable of setting up to do exactly what HVO are. Where's there's demand other companies enter the market. sikhthetech - 15 Sep 2023 - 11:51:42 - 4671 of 7212 hVIVO plc - HVO discojames, "Why would you need a facility there when all you are doing is testing vaccines? You ship the vaccine to the UK, you don't shift an established team, open a new facility, convince asian governments on every aspect of human challenge studys, virus containment just to have a physical presence." Where is the biggest vaccine manufacturer? India. If there is demand then organisations will adapt and setup in the area. Nothing stopping Indian, Chinese or any other country's companies from setting up a facility more 'locally'. You don't shift a team, you train and setup a new team/partner with a local organisation. If HVO don't someone else will. This was a valid point made by Chica. I disagreed with him only on the point that Indian companies could easily setup the facility without HVO. sikhthetech23 Feb '23 - 12:12 - 2312 of 4670 Edit chica "Expansion to India would indeed be a game changer,no shortage of healthy young volunteers there." Why would it be a game changer? If there's demand then why wouldn't an indian company (or any other company) setup and provide the same services, which is a point I've raised before?" |
Posted at 09/4/2024 09:47 by blackhorse23 Revenue 56m but MCAP 200m , it's overvalued stocks. So no room for improvement. Other health care companies eg APH revenue 190m & MCAP 180m. ROOM FOR IMPROVEMENT. HVO is research company but APH has their own products to sell. Again AZN mcap lower than revenue.I think hvo should buy back share rather than dividend |
Posted at 08/4/2024 15:02 by sikhthetech Chica,Exactly my point. CF dumped majority of his holding in HVO so soon after the company was talked up and before HVO's fy results. He then launches another venture, just before HVO's fy results, hoping to encourage HVO PIs to join in. That's why I believe HVO was talked up. To encourage investors into HVO, push the price up, so he could sell, once he's in profit, in order to launch his new venture. |
Posted at 12/3/2024 01:48 by lauders The dividend hasn't been announced yet and will be known next month when the results are released. It will be a "nominal dividend" so if you are focused on the dividend HVO is not for you. The future potential is what you should be focused on here and the hopefully under-promise and over-deliver scenario that Mo and team have recently been providing, despite what some "contributors" here may want you to believe! |
Posted at 08/2/2024 20:10 by sikhthetech Chicha,Have you looked at and thought about HVO business model? Big pharma work with them because they can pay a few mil to HVO in the hope they can get their vaccines/drugs to br success n to marker sooner than would normally happen. They largely paid for the new facility so they get favourable treatment from HVO in return. Nothing to do with liking HVO. If there's huge demand, what's stopping another company/pharmas setting up similar clinics? |
Posted at 05/2/2024 17:44 by sikhthetech 1gw"I think while we have a poster who is making disingenuous comparisons between HVO and TLY," Typical lies and BS from you and your mates. Anything to con readers. TLY share price goes down, you and your mates want to mention TLY. TLY share price goes up and you and your mates don't want to mention TLY. Nothing wrong with anyone posting opinions. You post and spin different views on the same metrics, depending on whether you and your mates are ramping or deramping. You and your mates are rattled. Stop your lies and be honest for once. Evidence of you comparing TLY to whatever share you and your mates are ramping...when it suits your agenda!!! . HVO: You posted a graph comparing TLY to HVO 1gw12 Dec '23 - 21:25 - 5463 of 6417 0 10 0 A visual aid. HVO in black vs TLY (rebased) in blue, starting at last year's close (10p HVO). 1gw13 Dec '23 - 20:57 - 5523 of 6417 0 6 0 In case the earlier chart wasn't specific enough: 30th Dec 2022: TLY 33.75p, HVO 10p 13th Dec 2023: TLY 4.9p, HVO 21.9p £100 invested in TLY at 30th Dec close price now worth £14.52 £100 invested in HVO at 30th Dec close price now worth £219.00 Not just HVO. Look at RTHM, even though I said it's the wrong thread, you continued. BYOT: 1gw6 Oct '19 - 13:34 - 3754 of 12442 0 3 1 The comparison with tly is relevant because of the similarity of the acquisition model, with tly paying 7x (ebitda or profit) contingent consideration and byotrol paying 9x (according to earlier finnCap note). Given you portray as a well researched poster, why do virtually all your shares crash? How many multiple ids do you have and why? Byot down 95% Trmr down 80% RTHM down 80% STU bust INSE down 60% etc etc |
Posted at 30/1/2024 11:15 by rivaldo Taken from another bb - Paul Scott on Stockopedia (who I often disagree with) is very keen on HVO now. The poster seems to have cut the post off slightly before the end:"HVIVO (LON:HVO) Up 6% to 27.75p (£189m) - Trading Update - Paul hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces an unaudited trading update for the year ended 31 December 2023. Revenue up 16% to £56m (slightly ahead of Cavendish previous forecast £55m) EBITDA margins of c.22% (2022: 18.7%) Cavendish now forecasts £12.8m adj EBITDA (previously £11.5m), an 11% upgrade today. This becomes forecast adj PBT of £10.5m (previously £9.2m), a 14% upgrade today. Adj EPS is increased from 1.3p to 1.5p, a PER of 18.5x - looks very reasonable to me, given the strong growth trajectory. Outlook - HVO guides £62m revenue for 2024, 11% increase. That looks a fairly soft target, so hopefully can be beaten. Excellent visibility - “90% of 2024 revenue guidance already contracted and good visibility into 2025” “Weighted contracted orderbook of £80 million as at 31 December 2023 (31 December 2022: £76 million)” “New medium-term target of growing Group revenue to £100m by 2028” R&D tax credits look a useful contributor to profit - …the Group also recognised Other Income relating to R&D tax credits of £2.6 million (2022: £2.2 million). Cash - it gets paid a lot up-front, which is an attractive feature of this share (demonstrating pricing power, and client commitment) - hVIVO is a highly cash generative business with cash of £37.0 million as at 31 December 2023 (31 December 2022: £28.4 million). This increase in cash generation is due to improved margins and the upfront non-refundable quarantine booking fee from new contracts. Dividends - it says annual divis will commence, more details to follow. New premises are coming on stream soon, which should help further growth - The new facility will substantially boost our revenue potential and should lead to improved operational efficiencies and enhanced margins. Paul’s opinion - this all reads very well I think. Despite a strong recent surge in share price, I think today’s forecast upgrade (FY 12/2023) and positive outlook makes the valuation still reasonable, and the visibility for 2024 looks excellent, with more earnings beats looking likely. I’m struggling to think of another company that has established such a superb growth track record, yet is still reasonably priced. Hence I’m more than happy to retain my positive view of HVO shares. Kicking myself for having got bored and sold mine in 2023, but never mind. Patience is the difficult bit with investing isn’t it, especially when shares are going nowhere for a while despite good news/figures - you start doubting your own judgement I find. We’re always learning! HVO shares have been volatile in the past, but the hype of the past has now been transformed into very strong fundamentals, so this recent rise seems far better underpinned by reality - which is also reflected i" |
Posted at 10/1/2024 12:09 by rivaldo Great to see the continuing rise here, and on terrific volumes too.FYI Paul Scott on Stockopedia summarised HVO positively ;ast week (I've had to leave out his charts): "Paul’s Section hVIVO (LON:HVO) £6.3m contract signed – Paul – GREEN Checking our previous notes, we steadily became more enthusiastic about HVO as 2023 progressed, moving in stages from amber up to green by 13/12/2023 (ahead expectations update), and 12/9/2023 (good interims, and forecasts raised). Well done to patient holders, as it’s had a smashing move up recently, in the almost everything rally we’ve seen in Nov-Dec 2023. The positive newsflow continues today - …signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV – common cold virus) Human Challenge Study Model… Revenue will be recognised in both FY 12/2024 and FY 12/2025. HVO’s new state-of-the-art quarantine facilities in Canary Wharf will be used. Broker update – Cavendish helps us with an update. It leaves forecasts unchanged, but they’re looking quite modest, given the strong newsflow. So I suspect beats against forecasts are likely for both 2023 and 2024. As you can see below, there’s already been an impressive upward trend in forecasts, and I’m pretty sure this is all organic growth too. Paul’s opinion – HVO really seems to be on a roll, and is producing very impressive newsflow. It’s increasingly looking like one of the UK market’s best growth companies. Valuation doesn’t seem particularly stretched, once you factor in likely beats against forecast. I also like that cash is received up-front from clients. Despite a strong surge in share price, I remain positive on HVO shares, so it’s GREEN again. Shares have been volatile in the past, but this current bull run looks much more firmly based on excellent company fundamentals" |
Posted at 07/1/2024 16:52 by 1gw For those keen to see evidence of increasing institutional ownership, we have got Canaccord Genuity disclosed as a 3%+ shareholder with 21,680,000 shares on the HVO site.This was first reported on here by m5 in his post 5055 (18th October). As far as I can see this is through their Marlborough funds. The 31st July 2023 fund manager's reports disclose the following holdings in HVO (as of 31st July): 11,680,000 Marlborough Nano-Cap Growth Fund 5,000,000 Marlborough UK Micro-Cap Growth Fund hXXps://www.trustnet hXXps://www.trustnet [advfn doesn't seem to like trustnet links, so you'll have to edit the link to restore the https] Click on Managers Report-Final at the bottom of each page to access the report with the individual holdings and search for hvivo. If you then look at Morningstar, you can see that it reports the UK Micro-cap Growth fund at 10m shares. 11.68m in the Nano-Cap fund and 10m in the UK Micro-cap fund would agree with the 21.68m reported on the HVO website. The implication is that Canaccord bought 5m HVO shares between 31st July and 18th October (date of M5's post) for their UK Micro-Cap growth fund. Finally, on Canaccord/Marlboroug The other big increase reported on the Morningstar page is River & Mercantile UK Microcap Growth Fund, which it reports as a new position of 6.6m shares. This is confirmed by their Final Manager's Report for the year ended 30th September 2023. hXXps://www.trustnet In the report they give the following commentary: "We initiated a position in hVIVO, a specialist outsourced provider of human challenge trials for testing infectious and respiratory disease treatments. Growth in this relatively nascent market – in which hVIVO has a dominant position – has been catalysed by changing ethical attitudes and greater regulatory recognition post COVID. The increasing quantity and size of trials is driving revenue growth with improving utilisation. hVIVO is attractively valued with earnings momentum supported by a growing order book and increased capacity as it relocates to a new larger facility. Human challenge trials help hVIVO’s pharma and biotech customers bring vital medical products to market faster and more cost-effectively resulting in better patient and societal outcomes. hVIVO’s key IP is in the manufacture of challenge agents, where it is the only company whose data on model efficacy has been approved by regulators. hVIVO upholds high ethical standards and, importantly, compensation for volunteers is both regulated and in line with minimum wage. As a result, hVIVO is currently ranked S2 – we do not see sustainability trends as a material positive or negative factor – with the potential to transition to S1 – material beneficiary of sustainability trends – as the company develops its own sustainability strategy." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
